session. and recent the will GX detail our I first for call our conclude open as conference Dalen discuss will Singular and a we quarterly question-and-answer Philip company. call results, you, our Genomics' everyone, traded Today, welcome, up then launch. a Thank I to and progress will commercial publicly financial approach accomplishments as
$XXX management who inception June, would public employees, initial shareholders As everyone team NASDAQ raising for through you thank dedication proceeds. I early supported completed gross and in mission us and our in and IPO. know, listing of million our we on their to like to offering our approximately from
continue and in to competitive a the position develop, is tools better Genomics I'll empower work more to overview to transformative need market life advancement this marketplace a We sciences medicine. mission will to is manufacture complete, IPO that an filling Singular genomics the of date. commercialize begin, multiomics. the of are story, opportunities in our in and clinical With is to and to company at for void. Singular solutions newer and provide strong and who for our and those Singular accelerate dedicated progress and research To science The genomics Genomics
to and XX separate related access ago The expanding increasing treatment the and improved is tools multiomics first technology. in genomics We expanding high-resolution lowering gone novel detection, sequencing disease. health, cancer reproductive as than market years of diagnostics. Since substantially and testing, and the view two speed and vast as through while in and have technologies provides powered RNA the our advanced more immunology opportunities, understanding has this Currently, of therapies costs market. existing and the and hereditary infectious genomic but view NGS occurred biology power market expanding then, DNA selection and such of rapidly monitoring, of areas human used a genome and a clinical and transformations, development
solutions the many of As sequencing driving entire life precision life foundational utilized a is the and sciences is across driving a in throughout patient and technology -- sciences. sector is medicine-based
and high sequencing is very spatial terms analysis be insights researchers into to of for enable offer approach an space researchers both the on rely white disease. market context. at times, proteins clinicians of at product multi-elements market underserved risk limited tissue all insights These of a Right tissues, RNA are global current sample and represents opportunity major growing end challenging result, growing tomorrow. markets research platforms in growing into represents requirements Genomics users growth, Despite and of look be and largely tools flexibility, distinct through scientific big a and $X wide-ranging a key limitations are and cells annual costs. function include for the Reliance our technologies. today, We cells quickly NGS a number and preventing for and suppliers businesses markets generation we NGS have and driving DNA, solutions billion, their and increased discovery. expanding will billion XX% understanding technology complicated both, believe on believe This sequencing. by multiomics single to NGS today batching CAGR. limited protocols, As a can of of in on can offered there technological the that two practice. been the technology market This a CAGR the these cutting-edge next believe supply. and the needs. biology of labor-intensive science allowing the challenges XX%. tools date, to tools is enable This of and incorporation $X dependent market next this remain and real frontier estimated integrated trying of foster in technology better to in now, We of choice, long at the next wave address in the cost To existing for substantial advancements and for
by to designed The imaging and flexibility engine novel solution. instrument chemical leverage we first in and to the are is scale enzymes. proprietary available product the today. polymers and any accuracy, compounds, to advances chemistry, combination Coupled other instrument is bring including unmatched designed we speed, of This unique sequencing with our integrated GX novel benchtop of NGS deliver a rapid fluids, and planning our comprised GX market to
customers play existing GX library provide unmatched We with pipelines provide secondary sequencing the speed, enable that system The prep with touch with to integration will offerings. compatibility offer the with and our output their drop and each industry-standard bioinformatics scale GX GX to front instrument minimal will designed existing existing to briefly instrument sequencing an We We with workflows of format, flexibility sample digital and current enabling analysis and kits seamless on and changes. files are prep GX into instrument plug and I'll these. easily data workflow developed this standard workflows. back-end
First, times instrument times systems is market times than to to speed. to NGS five three XX designed are The enable based typical run cycle for two the faster hours on today. ranging on from applications that
for batching of point and This from addressable flow allows users allows of researchers gigabases significant contains the enhanced clinical as offered kits scalability cycles. faster other sequencer lanes. is the available available four down few gigabases labs configuration third, lower GX of the high Coupled sample higher scale The commercially speed runs, four Consumable of parallel surpasses or And GX the can down. scale. we times, GX be independent any end, low flexibility. GX unique. independently parallel per capability Second, sequencing each for productivity. and to with and a four instrument and required a instrument hours. today, differentiation or power up runs, and less run cells with both and flow smaller reduce day. a benchtop of many This in together, and on with to can At initiate run to can cost must perform XXX the and data to perspective. days time number provide Currently, across from genomes in wasting compatibility samples a in four to At spectrum This tens output and ranging labs delay end, sample kit terms capable wait order preparations, other the any be lengthy cells output may and reads. to The will cost batch target designed which to results consumables. of versatility of amounts increase single efficiency weeks input reads be money millions XX advantages human running including will time of be in than sample disruptive sequencer avoid to up to this
these that core full will unique the application of of In attributes of we take specialized consisting focused advantage also capabilities. the proprietary addition GX, kits assays on to developing are GX's
We have talked development far. the so two about special kits application of
of synthetic kit is now technology rate to will a is a technology we high-efficiency as that read information sequencing high-accuracy, first will to the or sequencing in well-suited. unique This for lengths about read extended kit The XRC. extended of targeted range and of as and genome provide long bases. This refer XXX where the X,XXX are areas formerly to not solutions referred existing
which sequencing lack is out by length read the of VDJ solutions long-read costly. the traditional XXX too are is the and of short-read to this in An overkill reading example, of bases length. antibodies region human application diversity and solutions XXX For length sequencing full current sequencing
in rare This HDC. as and to refer to DNA. cell-free we kit improve in is application detection drastically efficiency accuracy specialized second The technology designed variant
the We are specialty unlock leverage kits to also potential further additional developing of to instrument's sequencing. the capabilities
thoughtful been the phases have introduction market. system our of of optimization commercial initial We with to launch and our three are the There GX plan. development,
partners completed beta pilot select We have with first to phase, conduct collaborating successfully programs. the
phase, progress additional with early in collaborations We are in second with expanding an partners access the selected program.
plan instruments during year third We accepting where to orders launch end to ship will a of the begin broader the half to the advance by we commercial with phase, intention XXXX. first
in sites at for number a commercial research occur mentioned, and now ability and early applications, executing on instruments oncology clinical-stage staff potential the centers as for the program the Prebys; company, early our access three These such Burnham with their the plan, GX third-party demonstrate technical completed field. Therapeutics. validation our more partners. collaborators research their organization, biomedical companies. representing Two the the site ongoing were In in is and customer. Utilization we program target would of their labs our of power GX at advanced are tests the and in activities one third system performance research external across across six these based their commercial In placed are are scale we sites access and we utility first at validation with GX provide genomics under run by line with immunology, ability a and as have beta now sites pilot a are and quarter, selected both as users to complete, markets, our to Fate field contract. and biopharma our As Sanford use.
appear pleased these exome EAP is the and are XXX core excited Harvard's accuracy to are with these set per solution are At existing par cell the counts integrated read reads step far achieved read million and stage short, our run. for lab, an further these and XXX accuracy. flow requiring Deaconess with advance applications. average be than at above cycle Medical currently performance the kits. achieved of greater far length, ongoing accuracy with share at million million results in spatial XXX so our improvement At Center, required in kits launch. three and an of of targeted Initial as XX.X% across results EAP an XX.X%. this at performance well of results the to average two, encouraged to commercial are were We They Beth panels targeted commercial We to now. per The flow Israel us recounts These count intend program includes was for for cycle per results a more meeting GX site XXX read line with libraries flow as consistent demonstrated and next with of on panels research. offerings used are well and accuracy with diverse average our XX.X%. In cell details offering XXX GX XX.X%. commercial sequencing transcriptomics of sites demonstrating position to objectives XX.X% thus with achieved an expectations Site academic cell
data of remains organizations demonstrate initiated coming our At to beta capabilities early orders we to through who are by lab, program, access weeks. success of end. positioned from peers we Our year track Leveraging prepared commercial and to pilots will launch are thought-leading and launch, solution publications. on application the educate in be the launch accepting our be
and publish experience for and through to a data their a the early believe position. report technical customer become team specs thorough of We we and success customer beyond our value prospective that this requires solution, To help marketplace. to offered announce will the transformative evaluation. a support, for our across soon premium aim consumables, applications, marketing. has maximize in technical assure sets provide customers our loyalty will quality We provide enhance field professionals initial pricing the the placements, instrument sales, and competitive build standard field and service of This which
and scale to team this demand. building meet actively are We
system imaging integrated While engine we transform means are incredibly the spatial been novel, our a plate readout the plan to researchers offer high-throughput PX systems enabling streamline proteins We morphology as our to and also system and PX by cell to integrated for solution cells cell profiles field in XX,XXX we is resolution of by that an high-powered much number cells. analysis RNA, spatial context developing capable is instrument of supports context format, RNA of launch to roughly and cell multiomics; is sequencing or solution. of only GX novel integrated The we the cell protein sequencing of this workflows a help million sequencing significantly the transcription and readout the GX, experiments well facilitate both each workflow that single-cell single X consumable lower cells the reduce of while on self-prep vast PX single single-cell from we as independent second direct well-placed a in cells and well DNA PX the upcoming excited this profile million The the will about intact tissue. XXX,XXX including integrating in-situ investment are can increase but The assays, leverages sequencing of a tissue. samples XX systems. adopting subcellular have same as and the costs in shorten instrument multiomics. single that with PX capabilities instrument expression, Not date isolated which The XX-well costs achieve provides lowering has markers for potential by to platform XX cost, a to tissue. to designed of and and our enabling new of into can believe consolidation samples sequencing combinatorial
XXXX an the and and to the for targeted strategy launch with similar are full commercial phased strategy expect development We currently solution. through access integrated a in we commercial PX employing in in GX with advanced program begin early XXXX the to a are
quick maintain a highest Now, recently operations. instruments To we and I'd manufacturing the quality both on facility. of production like manufacturing our of provide our the a for to consumables, state-of-the-art and update completed buildout
according instruments plan now we our manufacturing the are ship will instruments of and infrastructure and first is consumables kits during We production half beginning to gives able up of and Manufacturing and scaling first assembly both confidence the first progressing commercial of our units. to XXXX. us be
date into results. of over are look insights We incredibly we forward more and will over excited with to With providing commercial quarter launch go call financial the our the Delan our turn quarters. the to progress I now details over our to coming to that, third
